Indication
Skin inflammation
Skin inflammation is a localized or widespread immune-mediated response occurring within the integumentary system, affecting cutaneous tissues across pediatric and adult populations. Read more about Skin inflammation
893 drugs 214 manufacturers
Drugs that treat it
Common Skin inflammation therapies.
FLUOCINOLONE ACETONIDE
BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE
FLUOCINONIDE
FLUTICASONE PROPIONATE
HYDROCORTISONE
MOMETASONE FUROATE
TRIAMCINOLONE ACETONIDE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSkin inflammation is a localized or widespread immune-mediated response occurring within the integumentary system, affecting cutaneous tissues across pediatric and adult populations.
It develops when innate or adaptive immune pathways are activated by external triggers, such as pathogens, allergens, and mechanical trauma, or by intrinsic dysregulation seen in dermatoses like eczema, dermatitis, and psoriasis.
Pathophysiologically, the process involves barrier disruption, keratinocyte activation, release of pro-inflammatory cytokines, and the infiltration of leukocytes such as T cells, neutrophils, and mast cells into epidermal and dermal layers.
Clinically, it manifests through cardinal signs of inflammation, including erythema, edema, localized warmth, pruritus, pain, and secondary epidermal changes such as scaling, blistering, or lichenification.
- nih.gov
Skin inflammation is a localized or widespread immune-mediated response occurring within the integumentary system, affecting cutaneous tissues across pediatric and adult populations It develops when innate or adaptive immune pathways are activated by external triggers, such as pathogens, allergens, and mechanical trauma, or by intrinsic dysregulation seen in dermatoses like eczema, dermatitis, and psoriasis
- nih.gov
Skin inflammation is a localized or widespread immune-mediated response occurring within the integumentary system, affecting cutaneous tissues across pediatric and adult populations It develops when innate or adaptive immune pathways are activated by external triggers, such as pathogens, allergens, and mechanical trauma, or by intrinsic dysregulation seen in dermatoses like eczema, dermatitis, and psoriasis Pathophysiologically, the process involves barrier disruption, keratinocyte activation, r...
- nih.gov
It develops when innate or adaptive immune pathways are activated by external triggers, such as pathogens, allergens, and mechanical trauma, or by intrinsic dysregulation seen in dermatoses like eczema, dermatitis, and psoriasis
- nih.gov
It develops when innate or adaptive immune pathways are activated by external triggers, such as pathogens, allergens, and mechanical trauma, or by intrinsic dysregulation seen in dermatoses like eczema, dermatitis, and psoriasis Pathophysiologically, the process involves barrier disruption, keratinocyte activation, release of pro-inflammatory cytokines, and the infiltration of leukocytes such as T cells, neutrophils, and mast cells into epidermal and dermal layers
- medlineplus.gov
Clinically, it manifests through cardinal signs of inflammation, including erythema, edema, localized warmth, pruritus, pain, and secondary epidermal changes such as scaling, blistering, or lichenification
- topicrem.com
Clinically, it manifests through cardinal signs of inflammation, including erythema, edema, localized warmth, pruritus, pain, and secondary epidermal changes such as scaling, blistering, or lichenification
Personalize your experience
Follow Skin inflammation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.